Balance Sheet
Growth Metrics
Income Statement
Others
EBIATReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Gsk (GLAXF) Non-Current Receivables (2016 - 2018)

Gsk has reported Non-Current Receivables over the past 3 years, most recently at $181.4 million for Q4 2018.

  • Quarterly results put Non-Current Receivables at $181.4 million for Q4 2018, down 39.8% from a year ago — trailing twelve months through Dec 2018 was $181.4 million (down 39.8% YoY), and the annual figure for FY2018 was $188.3 million, down 35.6%.
  • Non-Current Receivables for Q4 2018 was $181.4 million at Gsk, down from $301.4 million in the prior quarter.
  • Over the last five years, Non-Current Receivables for GLAXF hit a ceiling of $353.1 million in Q4 2016 and a floor of $181.4 million in Q4 2018.
  • Median Non-Current Receivables over the past 3 years was $301.4 million (2017), compared with a mean of $278.6 million.
  • Biggest five-year swings in Non-Current Receivables: fell 14.64% in 2017 and later tumbled 39.8% in 2018.
  • Gsk's Non-Current Receivables stood at $353.1 million in 2016, then dropped by 14.64% to $301.4 million in 2017, then tumbled by 39.8% to $181.4 million in 2018.
  • The last three reported values for Non-Current Receivables were $181.4 million (Q4 2018), $301.4 million (Q4 2017), and $353.1 million (Q4 2016) per Business Quant data.